Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Triveni Bio raises $65 million Series C financing, co-led by Ascenta Capital and Janus Henderson Investors for clinical studies expansion.
PRIVATEJun 17, 2026•about 2 months ago
Amount Raised
$65 Million
Round Type
Series C
WalthamBiotechnologyHealth Care
Investors
Deep Track CapitalJanus Henderson InvestorsAscenta Capital
Description
Triveni Bio Inc. has announced a $65 million Series C financing round to support its pipeline expansion and corporate growth. The financing, co-led by Ascenta Capital and Janus Henderson Investors, will enhance the clinical development of TRIV-573. This investment will facilitate a Phase 2 clinical trial for atopic dermatitis
Company Information
Company
Triveni Bio
Location
Waltham, Massachusetts, United States
About
Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact.
Related People
Suggested for you
2 contacts
Verified contactsBhaskar S., Chief Medical Officer hidden
Predictive Intelligence
Strategic
ML-powered predictions for Triveni Bio's next move
WalthamBiotechnologyHealth Care